Sugi Predict

Sugi Predict / Compounds / SCHEMBL5267939

SCHEMBL5267939

SCHEMBL5267939

O=C(OCc1ccccc1)N1CCC[C@@H]1CO

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SPHK2 Q9NRA0 1/20 0.58
▸ PREP P48147 3/20 0.56
▸ ACE2 Q9BYF1 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ CTRB1 P17538 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.52
▸ CYP2C19 P33261 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ KLK7 P49862 1/20 0.51
▸ KLK5 Q9Y337 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602602 1.00 SPHK2 (0.58) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL809494 1.00 SPHK2 (0.58) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL1190565 0.96 SPHK2 (0.54) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL80752 0.96 SPHK2 (0.54) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL3605585 0.96 SPHK2 (0.54) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL7561453 0.95 SPHK2 (0.53) SPHK2PREPACE2SMN1; SMN2NPC1
SCHEMBL6252758 0.92 SMN1; SMN2 (0.56) PREPSMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL4186350 0.92 SMN1; SMN2 (0.56) PREPSMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL4186357 0.92 SMN1; SMN2 (0.56) PREPSMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL10749955 0.90 PREP (0.67) SPHK2PREPCTRB1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688790-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-01-29 — — US disclosed
WO-2024211712-A1 CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-10-10 — — WO disclosed
US-20230293535-A1 ERBB/BTK INHIBITORS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2023-09-21 — — US disclosed
US-20170342058-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2017-11-30 — — US disclosed
US-9682965-B2 Fumagillol heterocyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-06-20 — — US disclosed
US-9682965-B2 Fumagillol heterocyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-06-20 — — US disclosed
US-20170066749-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2017-03-09 — — US disclosed
US-20170066749-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2017-03-09 — — US disclosed
WO-2017027684-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2017-02-16 — — WO disclosed
US-20040171639-A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2004-09-02 — — US disclosed
EP-1392651-A1 HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-03-03 — — EP disclosed
WO-2002090326-A1 HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-11-14 — — WO disclosed
US-5637731-A CHOLINERGIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-10 — — US disclosed
US-5550257-A TREATING CENTRAL CHOLINERGIC DYSFUNCTION AMERICAN CYANAMID COMPANY (US) 1996-08-27 — — US disclosed
US-5451685-A MANUFACTURING PHARMACEUTICALS AMERICAN CYANAMID COMPANY (US) 1995-09-19 — — US disclosed
US-5356885-A Cholinergic agents; administering for treatment of diseases of the central nervous system AMERICAN CYANAMID COMPANY (US) 1994-10-18 — — US disclosed
EP-0510333-A1 Substituted oxotremorine derivatives AMERICAN CYANAMID COMPANY (US) 1992-10-28 — — EP disclosed
US-4902684-A Benzazepine and benzothiazepine derivatives E. R. SQUIBB & SONS, INC. (US) 1990-02-20 — — US disclosed
WO-1989012633-A1 BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES E.R. SQUIBB & SONS, INC. (US) 1989-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066749-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FAP, FOLH1 SPHK2 2059/4885PREP 6/4885ACE2 46/4885
US-20170342058-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FAP, FOLH1 SPHK2 2059/4885PREP 6/4885ACE2 46/4885
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS KRAS, NRAS, HRAS SPHK2 3174/4885PREP 4152/4885ACE2 1026/4885
US-20040171639-A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists TRPV1, UTS2R, GPR17 SPHK2 4301/4885PREP 1657/4885ACE2 1089/4885
US-20230293535-A1 ERBB/BTK INHIBITORS ERBB2, BTK, ERBB3 SPHK2 696/4885PREP 4001/4885ACE2 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.